CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE

Detalhes bibliográficos
Ano de defesa: 2020
Autor(a) principal: Felipe Bruno Dias de Oliveira lattes
Orientador(a): Mario Ferretti Filho lattes
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Faculdade Israelita de Ciências da Saúde Albert Einstein
Programa de Pós-Graduação: Acadêmico em Ciências da Saúde
Departamento: Não Informado pela instituição
País: Brasil
Palavras-chave em Português:
Palavras-chave em Inglês:
Link de acesso: https://repositorio.einstein.br/publicacao/171840
Resumo: Introduction: Osteoarthritis is a progressive joint disease that mainly affects the articular cartilage, causing joint degeneration, pain and limitations on locomotor performance. Cell therapy, using mesenchymal stem cells, for cartilage regeneration has proved to be a viable alternative for treatment of osteoarthritis due to this therapy broad immunomodulatory action. However, the optimal route of cells delivery still needs to be identified (intra-articular or intravenous) to optimize cells transplantation. Purpose: To evaluate the administration routes for systemic (intravenous) or local (intra-articular) cell transplantation regarding their regenerative capacity for articular cartilage. Methods: This was an animal model (rat) study of osteoarthritis induced by medial meniscus destabilization surgery or by false surgery without injury. In vivo cell tracking was performed by bioluminescence, imaging flow cytometry, and confocal microscopy. The pro- and anti-inflammatory immunomodulation in serum and synovial wash samples were assessed by magnetic beads multiplex, and the regenerative capacity of transplanted cells were histologically evaluated. In addition, gait, functional performance and lower limb muscle balance were also evaluated. Results: After nine weeks, the animal model used did not change gait pattern, but reduced functional performance and developed muscle atrophy of quadriceps, gastrocnemius/soleus, and anterior tibialis. The transplanted cells remained viable on the operated knee up to one week after intra-articular transplant. Bioluminescence (8 hours; N=1) and positive events were detected by imaging flow cytometry (12 hours; N=2) in the injured knee after the intravenous cell transplantation. The main cytokine changes occurred within 24 hours after the cell transplantation with increased expression of MCP-1 and RANTES for the intra-articular route, MIP-1a, and IL-10 for the intravenous route. This expression decreased after one week in both routes. The immune suppression of inflammatory cytokines occurred mainly for the intra-articular cell transplantation (MCP-1, RANTES, MIP-1a, IL-18) compared with placebo. This suppressive effect was also observed in synovial wash samples regarding concentration of IL-18 four weeks after intra-articular cellular transplant than that of placebo. Intravenous cellular treatment did not show the same immunosuppressive effect in the short term, and also showed a higher concentration of IL-1ß one week later compared with intra-articular route. However, the treatment showed a reduction of RANTES in the long term over four and 12 weeks later compared with placebo transplantation. Intra-articular cell transplantation reduced muscle atrophy of anterior tibialis up to four weeks after the treatment compared with intravenous cell transplantation and intra-articular placebo. No histological changes of reduced articular cartilage degeneration were seen for any of the evaluated route or time after transplantation. Conclusion: The destabilization of medial meniscus in rats proved to be of slow developing and showed similar characteristics to human osteoarthritis. In addition, a single intra-articular or intravenous transplantation with mesenchymal stem cells was not enough to reduce the progression of osteoarthritis observed in the animal model, i.e., nine weeks after surgery regardless of the time studied. Despite the evidence of homing capacity for systemically transplanted cells and long-term effect over one inflammatory cytokine, our analyses showed cells with more evident immunosuppressive and tissue activity in locally transplanted cells for osteoarthritis treatment.
id HAE-1_c9fb415a3c8e40bba25fd1f9b7fc2d8a
oai_identifier_str oai:repositorio.einstein.br:171840
network_acronym_str HAE-1
network_name_str Repositório Einstein de Produção Intelectual (REPI)
repository_id_str
spelling porCAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSERegenerative capacity of systemically and locally administered mesenchymal cells in an animal model of osteoarthritisIntroduction: Osteoarthritis is a progressive joint disease that mainly affects the articular cartilage, causing joint degeneration, pain and limitations on locomotor performance. Cell therapy, using mesenchymal stem cells, for cartilage regeneration has proved to be a viable alternative for treatment of osteoarthritis due to this therapy broad immunomodulatory action. However, the optimal route of cells delivery still needs to be identified (intra-articular or intravenous) to optimize cells transplantation. Purpose: To evaluate the administration routes for systemic (intravenous) or local (intra-articular) cell transplantation regarding their regenerative capacity for articular cartilage. Methods: This was an animal model (rat) study of osteoarthritis induced by medial meniscus destabilization surgery or by false surgery without injury. In vivo cell tracking was performed by bioluminescence, imaging flow cytometry, and confocal microscopy. The pro- and anti-inflammatory immunomodulation in serum and synovial wash samples were assessed by magnetic beads multiplex, and the regenerative capacity of transplanted cells were histologically evaluated. In addition, gait, functional performance and lower limb muscle balance were also evaluated. Results: After nine weeks, the animal model used did not change gait pattern, but reduced functional performance and developed muscle atrophy of quadriceps, gastrocnemius/soleus, and anterior tibialis. The transplanted cells remained viable on the operated knee up to one week after intra-articular transplant. Bioluminescence (8 hours; N=1) and positive events were detected by imaging flow cytometry (12 hours; N=2) in the injured knee after the intravenous cell transplantation. The main cytokine changes occurred within 24 hours after the cell transplantation with increased expression of MCP-1 and RANTES for the intra-articular route, MIP-1a, and IL-10 for the intravenous route. This expression decreased after one week in both routes. The immune suppression of inflammatory cytokines occurred mainly for the intra-articular cell transplantation (MCP-1, RANTES, MIP-1a, IL-18) compared with placebo. This suppressive effect was also observed in synovial wash samples regarding concentration of IL-18 four weeks after intra-articular cellular transplant than that of placebo. Intravenous cellular treatment did not show the same immunosuppressive effect in the short term, and also showed a higher concentration of IL-1ß one week later compared with intra-articular route. However, the treatment showed a reduction of RANTES in the long term over four and 12 weeks later compared with placebo transplantation. Intra-articular cell transplantation reduced muscle atrophy of anterior tibialis up to four weeks after the treatment compared with intravenous cell transplantation and intra-articular placebo. No histological changes of reduced articular cartilage degeneration were seen for any of the evaluated route or time after transplantation. Conclusion: The destabilization of medial meniscus in rats proved to be of slow developing and showed similar characteristics to human osteoarthritis. In addition, a single intra-articular or intravenous transplantation with mesenchymal stem cells was not enough to reduce the progression of osteoarthritis observed in the animal model, i.e., nine weeks after surgery regardless of the time studied. Despite the evidence of homing capacity for systemically transplanted cells and long-term effect over one inflammatory cytokine, our analyses showed cells with more evident immunosuppressive and tissue activity in locally transplanted cells for osteoarthritis treatment.Introdução: A osteoartrose constitui uma patologia articular progressiva, que acomete, principalmente, a cartilagem articular, causando sua degeneração, dor e limitações locomotoras. Terapia celular, com células-tronco mesenquimais, para regeneração da cartilagem, tem demonstado ser uma alternativa potencial no tratamento da osteoartrose, devido sua ampla atuação imunomoduladora. Porém, ainda se faz necessário identificar qual é a melhor via de administração celular (intra-articular ou intravenosa) para optimização do transplante. Objetivos: Avaliar as vias de administração para transplante celular sistêmico (intravenoso) e local (intra-articular), quanto à capacidade regenerativa da cartilagem articular. Métodos: Utilizou-se um modelo animal (rato) de osteoartrose, induzida por cirurgia de desestabilização do menisco medial ou por cirurgia falsa sem lesão; o rastreamento das células in vivo foi realizado por bioluminescência, citometria de fluxo de imagem e microscopia confocal; a imunomodulação pró e anti-inflamatórias no soro e lavado sinovial foram avaliadas por multiplex de beads magnéticas; a capacidade regenerativa das células transplantadas, avaliadas histologicamente. Também passaram por avaliação a marcha, a performance funcional e o equilíbrio muscular dos membros inferiores. Resultados: O modelo animal utilizado, após nove semanas, não alterou padrão de marcha, porém reduziu a performance funcional e gerou atrofia do quadríceps, gastrocnêmio/sóleo e tibial anterior. As células transplantadas permaneceram viáveis no joelho operado, até uma semana após transplante intra-articular. Foi possível detectar bioluminescência (8 horas; N=1) e eventos positivos, por citometria de fluxo de imagem (12 horas; N=2), no joelho com lesão após transplante celular intravenoso. As principais alterações de citocinas ocorreram, em até 24 horas após transplante celular, com aumento da expressão de MCP-1 e RANTES, por via intra-articular, MIP-1a e IL-10 por via intravenosa. Essa expressão se reduziu, após uma semana, para ambas as vias. Imunossupressão de citocinas inflamatórias ocorreram, principalmente, para o transplantecelular (MCP-1, RANTES, MIP-1a, IL-18), em comparação com o placebo. Esse efeito supressor foi observado, também, no lavado sinovial, quanto à concentração de IL-18, em quatro semanas, após transplante intra-articular de células em relação ao placebo. O tratamento celular intravenoso não apresentou o mesmo efeito imunossupressor em curto prazo, além de apresentar maior concentração de IL-1ß, após uma semana em comparação a via intra-articular. Porém, apresentou redução de RANTES a longo prazo, quatro e 12 semanas, em comparação ao transplante placebo. Contudo, o transplante celular intra-articular reduziu a atrofia muscular do tibial anterior, por até quatro semanas após tratamento, em comparação ao transplante celular intravenoso e ao placebo intra-articular. Não se fez possível observar alterações histológicas de redução, referentes a degeneração da cartilagem articular, para nenhuma via ou tempo, analisados após transplante. Conclusões: O modelo animal de desestabilização do menisco medial apresentou evolução lenta, com características similares a osteoartrose em humanos. Também, um único transplante intra-articular ou intravenoso de células-tronco mesenquimais não se mostrou suficiente para reduzir a progressão da osteoartrose, gerada pelo modelo animal, nove semanas após cirurgia, independente do tempo analisado. Apesar dos indícios de capacidade de homing das células administradas, sistemicamente, e controle, a longo prazo, de uma citocina inflamatória, as análises evidenciaram uma ação celular imunossupressora e tecidual, mais evidente para células administradas, localmente, no tratamento da osteoartrose.OsteoartriteRatos WistarTransplante de células-tronco mesenquimaisOsteoarthritisWistar ratsMesenchymal stem cell transplantationinfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/publishedVersionMario Ferretti Filhohttp://lattes.cnpq.br/4905984222936368Eliane Antoniolihttp://lattes.cnpq.br/2915764856338898http://lattes.cnpq.br/3148158941155928Felipe Bruno Dias de OliveiraFaculdade Israelita de Ciências da Saúde Albert EinsteinAcadêmico em Ciências da SaúdeBrasil2020https://repositorio.einstein.br/publicacao/171840oai:repositorio.einstein.br:171840doi:10.31744/PG2020.106984reponame:Repositório Einstein de Produção Intelectual (REPI)instname:Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)instacron:SBIBAEinfo:eu-repo/semantics/openAccessRepositório InstitucionalPRIhttps://repositorio.einstein.br/oai || https://api.einstein.br/prd/plataformacientifica/sgpcri/api/oai2repositorioinstitucional@einstein.bropendoar:2020-08-17T00:00Repositório Einstein de Produção Intelectual (REPI) - Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)falseoai:repositorio.einstein.br:171840
dc.title.por.fl_str_mv CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
dc.title.alternative.eng.fl_str_mv Regenerative capacity of systemically and locally administered mesenchymal cells in an animal model of osteoarthritis
title CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
spellingShingle CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
Felipe Bruno Dias de Oliveira
Osteoartrite
Ratos Wistar
Transplante de células-tronco mesenquimais
Osteoarthritis
Wistar rats
Mesenchymal stem cell transplantation
title_short CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
title_full CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
title_fullStr CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
title_full_unstemmed CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
title_sort CAPACIDADE REGENERATIVA DE CÉLULAS MESENQUIMAIS ADMINISTRADAS DE FORMA LOCAL E SISTÊMICA EM MODELO ANIMAL DE OSTEOARTROSE
author Felipe Bruno Dias de Oliveira
author_facet Felipe Bruno Dias de Oliveira
author_role author
dc.contributor.advisor1.fl_str_mv Mario Ferretti Filho
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/4905984222936368
dc.contributor.advisor-co1.fl_str_mv Eliane Antonioli
dc.contributor.advisor-co1Lattes.fl_str_mv http://lattes.cnpq.br/2915764856338898
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/3148158941155928
dc.contributor.author.fl_str_mv Felipe Bruno Dias de Oliveira
contributor_str_mv Mario Ferretti Filho
Eliane Antonioli
dc.subject.por.fl_str_mv Osteoartrite
Ratos Wistar
Transplante de células-tronco mesenquimais
topic Osteoartrite
Ratos Wistar
Transplante de células-tronco mesenquimais
Osteoarthritis
Wistar rats
Mesenchymal stem cell transplantation
dc.subject.eng.fl_str_mv Osteoarthritis
Wistar rats
Mesenchymal stem cell transplantation
description Introduction: Osteoarthritis is a progressive joint disease that mainly affects the articular cartilage, causing joint degeneration, pain and limitations on locomotor performance. Cell therapy, using mesenchymal stem cells, for cartilage regeneration has proved to be a viable alternative for treatment of osteoarthritis due to this therapy broad immunomodulatory action. However, the optimal route of cells delivery still needs to be identified (intra-articular or intravenous) to optimize cells transplantation. Purpose: To evaluate the administration routes for systemic (intravenous) or local (intra-articular) cell transplantation regarding their regenerative capacity for articular cartilage. Methods: This was an animal model (rat) study of osteoarthritis induced by medial meniscus destabilization surgery or by false surgery without injury. In vivo cell tracking was performed by bioluminescence, imaging flow cytometry, and confocal microscopy. The pro- and anti-inflammatory immunomodulation in serum and synovial wash samples were assessed by magnetic beads multiplex, and the regenerative capacity of transplanted cells were histologically evaluated. In addition, gait, functional performance and lower limb muscle balance were also evaluated. Results: After nine weeks, the animal model used did not change gait pattern, but reduced functional performance and developed muscle atrophy of quadriceps, gastrocnemius/soleus, and anterior tibialis. The transplanted cells remained viable on the operated knee up to one week after intra-articular transplant. Bioluminescence (8 hours; N=1) and positive events were detected by imaging flow cytometry (12 hours; N=2) in the injured knee after the intravenous cell transplantation. The main cytokine changes occurred within 24 hours after the cell transplantation with increased expression of MCP-1 and RANTES for the intra-articular route, MIP-1a, and IL-10 for the intravenous route. This expression decreased after one week in both routes. The immune suppression of inflammatory cytokines occurred mainly for the intra-articular cell transplantation (MCP-1, RANTES, MIP-1a, IL-18) compared with placebo. This suppressive effect was also observed in synovial wash samples regarding concentration of IL-18 four weeks after intra-articular cellular transplant than that of placebo. Intravenous cellular treatment did not show the same immunosuppressive effect in the short term, and also showed a higher concentration of IL-1ß one week later compared with intra-articular route. However, the treatment showed a reduction of RANTES in the long term over four and 12 weeks later compared with placebo transplantation. Intra-articular cell transplantation reduced muscle atrophy of anterior tibialis up to four weeks after the treatment compared with intravenous cell transplantation and intra-articular placebo. No histological changes of reduced articular cartilage degeneration were seen for any of the evaluated route or time after transplantation. Conclusion: The destabilization of medial meniscus in rats proved to be of slow developing and showed similar characteristics to human osteoarthritis. In addition, a single intra-articular or intravenous transplantation with mesenchymal stem cells was not enough to reduce the progression of osteoarthritis observed in the animal model, i.e., nine weeks after surgery regardless of the time studied. Despite the evidence of homing capacity for systemically transplanted cells and long-term effect over one inflammatory cytokine, our analyses showed cells with more evident immunosuppressive and tissue activity in locally transplanted cells for osteoarthritis treatment.
publishDate 2020
dc.date.issued.fl_str_mv 2020
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.einstein.br/publicacao/171840
oai:repositorio.einstein.br:171840
doi:10.31744/PG2020.106984
url https://repositorio.einstein.br/publicacao/171840
identifier_str_mv oai:repositorio.einstein.br:171840
doi:10.31744/PG2020.106984
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Faculdade Israelita de Ciências da Saúde Albert Einstein
dc.publisher.program.fl_str_mv Acadêmico em Ciências da Saúde
dc.publisher.country.fl_str_mv Brasil
publisher.none.fl_str_mv Faculdade Israelita de Ciências da Saúde Albert Einstein
dc.source.none.fl_str_mv reponame:Repositório Einstein de Produção Intelectual (REPI)
instname:Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)
instacron:SBIBAE
instname_str Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)
instacron_str SBIBAE
institution SBIBAE
reponame_str Repositório Einstein de Produção Intelectual (REPI)
collection Repositório Einstein de Produção Intelectual (REPI)
repository.name.fl_str_mv Repositório Einstein de Produção Intelectual (REPI) - Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)
repository.mail.fl_str_mv repositorioinstitucional@einstein.br
_version_ 1880933135814754304